MX9206309A - Metodo y composicion para tratar tumores que tienen alta actividad de tirosinasa. - Google Patents

Metodo y composicion para tratar tumores que tienen alta actividad de tirosinasa.

Info

Publication number
MX9206309A
MX9206309A MX9206309A MX9206309A MX9206309A MX 9206309 A MX9206309 A MX 9206309A MX 9206309 A MX9206309 A MX 9206309A MX 9206309 A MX9206309 A MX 9206309A MX 9206309 A MX9206309 A MX 9206309A
Authority
MX
Mexico
Prior art keywords
tyrosinase
thyrosinase
composition
high activity
glucuronic acid
Prior art date
Application number
MX9206309A
Other languages
English (en)
Inventor
David Rubin
Adolph Schwimmer
Original Assignee
David Rubin
Adolph Schwimmer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Rubin, Adolph Schwimmer filed Critical David Rubin
Publication of MX9206309A publication Critical patent/MX9206309A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Las células de tumor que tienen actividad de Beta- glucoronidasa y tirosinasa se tratan selectivamente mediante administración de un conjugado de un compuesto citotóxico que es un substrato para la tirosinasa y el ácido glucorónico o una sal o éster farmacéuticamente aceptable del mismo, particularmente la forma triacetilada del ácido glucorónico.
MX9206309A 1991-11-04 1992-11-03 Metodo y composicion para tratar tumores que tienen alta actividad de tirosinasa. MX9206309A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78734791A 1991-11-04 1991-11-04

Publications (1)

Publication Number Publication Date
MX9206309A true MX9206309A (es) 1994-05-31

Family

ID=25141186

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9206309A MX9206309A (es) 1991-11-04 1992-11-03 Metodo y composicion para tratar tumores que tienen alta actividad de tirosinasa.

Country Status (11)

Country Link
US (1) US5340803A (es)
EP (1) EP0619704B1 (es)
AT (1) ATE178211T1 (es)
AU (1) AU665220B2 (es)
CA (1) CA2122922C (es)
DE (1) DE69228829T2 (es)
DK (1) DK0619704T3 (es)
ES (1) ES2132137T3 (es)
GR (1) GR3030259T3 (es)
MX (1) MX9206309A (es)
WO (1) WO1993008688A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639737A (en) * 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
US5760008A (en) * 1991-11-04 1998-06-02 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting metastases of malignant tumors
US5476842A (en) * 1991-11-04 1995-12-19 Co Enzyme Technology Ltd. Method and compositions for treating tumors having high tyrosinase activity
US5543146A (en) * 1995-01-20 1996-08-06 Prostahelp, Inc. Dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland
DK1098641T3 (en) * 1998-07-27 2016-08-15 St Jude Pharmaceuticals Inc Chemically induced intracellular hyperthermia
US7927612B2 (en) * 2000-01-19 2011-04-19 Baofa Yu Combinations and methods for treating neoplasms
WO2002069953A1 (en) * 2001-03-01 2002-09-12 The Board Of Regents Of The University Of Texas System Methods of treating lung inflammation
EP1381349A4 (en) * 2001-04-27 2004-09-29 Gen Hospital Corp TYROSINASEBESTIMMUNG
CN1649600A (zh) 2002-02-28 2005-08-03 A&D生物科学公司 氟西汀及类似物的糖醛酰胺、苷和原酸酯苷及其应用
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
CA2484891A1 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
EP2065057A3 (en) * 2006-03-15 2009-08-12 Mallinckrodt Inc. Chelating conjugates having a substituted aromatic moiety and derivatives thereof
CN101138634A (zh) * 2006-09-07 2008-03-12 于保法 用于治疗肿瘤的组合物
CN107106531A (zh) 2014-11-26 2017-08-29 于保法 微创精准个体化肿瘤内化学诱导免疫治疗方法半抗原增强的化学免疫治疗
WO2016196614A1 (en) * 2015-06-01 2016-12-08 University Of Kentucky Research Foundation Chloroquine induction of par-4 and treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2212014A1 (de) * 1971-04-21 1972-10-26 Deutsche Akademie der Wissenschaf ten zu Berlin, χ 1199 Berlin Verfahren zur fermentativen Spaltung von Transportformen von Chemotherapeutika, insbesondere Cancerostatica
US4424348A (en) * 1978-10-13 1984-01-03 Adolf W. Schwimmer Methods of manufacture of nitrile-containing glucuronic acid conjugates
US4481195A (en) * 1978-10-13 1984-11-06 Adolf Schwimmer Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
US4337760A (en) * 1978-10-13 1982-07-06 Adolf Schwimmer Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
US4812590A (en) * 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma

Also Published As

Publication number Publication date
WO1993008688A1 (en) 1993-05-13
DE69228829D1 (de) 1999-05-06
AU3064192A (en) 1993-06-07
EP0619704A4 (en) 1997-03-26
GR3030259T3 (en) 1999-08-31
EP0619704B1 (en) 1999-03-31
DK0619704T3 (da) 1999-10-11
DE69228829T2 (de) 1999-10-21
AU665220B2 (en) 1995-12-21
CA2122922C (en) 2004-03-30
US5340803A (en) 1994-08-23
ES2132137T3 (es) 1999-08-16
CA2122922A1 (en) 1993-05-13
ATE178211T1 (de) 1999-04-15
EP0619704A1 (en) 1994-10-19

Similar Documents

Publication Publication Date Title
MX9206309A (es) Metodo y composicion para tratar tumores que tienen alta actividad de tirosinasa.
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
GEP20033117B (en) Hydroxy Pipecolate Hydroxamic Acid Derivatives as MMP Inhibitors, Pharmaceutical Compositions Containing Them and Their Use for Treatment of Diseases caused by MMP
BR0110420A (pt) Agonistas muscarìnicos
CA2418479A1 (en) Prodrugs of betulinic acid derivatives for the treatment of cancer
GEP20043322B (en) C7 Ester Substituted Taxanes as Antitumor Agents, Pharmaceutical Compositions Containing the Same and Use Thereof for Inhibiting Tumors
ATE296097T1 (de) Verwendung eines r-nsaid als chemoschützendes mittel zur behandlung kolorektales krebs
BRPI0510684A (pt) composições para adiministração tópica ou transdérmica de agente anticolinérgico ou antiespasmódico e uso dos respectivos compostos
PL351280A1 (en) Methods and compositions for treating solid tumors
AU7371600A (en) Use of alpha-linolenic acid metabolites for treatment or prevention of cancer
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
CA2406024A1 (en) Methods for improving size and appearance of a wound
ATE310506T1 (de) Biodegradierbare polyphosphoester- zusammensetzungen zur behandlung von ovarialkrebs
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
GR3031917T3 (en) Treatment of diseases caused by sebaceous gland disorders with acyl CoA cholesterol acyl transferase inhibitors
GB9903403D0 (en) Substituted stilbene compounds with vascular damaging activity
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
BR9908125A (pt) Composto, composto dimérico, composição farmacêutica, uso do composto, processo compreendendo inibir células de câncer, e, processo terapêutico
BR9405404A (pt) Uso de compostos de terpeno para reduzida liberação de ácido aracdônico e de mediadores de inflamação
JPS631287B2 (es)
GEP20043231B (en) Resorcinol Composition
UY26514A1 (es) " composición para el tratamiento de tejidos danados".
JIMBOW et al. Phenolic melanin precursors provide a rational approach to the design of antitumor agents for melanoma
ES2181407T3 (es) Glucocorticoides para tratar la glomerulonefritis.
ATE353639T1 (de) In-vitro-verwendung von astaxanthin zur vorbehandlung von zellen vor uv-bestrahlung zwecks hemmung der aktivierung von nf-kb